^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)

i
Other names: HS3ST2, Heparan Sulfate-Glucosamine 3-Sulfotransferase 2, 3OST2, Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase 2, Heparan Sulfate (Glucosamine) 3-O-Sulfotransferase 2, Heparan Sulfate Glucosamine 3-O-Sulfotransferase 2, Heparan Sulfate 3-O-Sulfotransferase 2, H3-OST-2, 3-OST-2, Heparin-Glucosamine 3-O-Sulfotransferase, 30ST2
Associations
Trials
1year
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)
over1year
Construction and experimental verification of a novel nine-glycosylation-related gene prognostic risk model for clear cell renal carcinoma. (PubMed, Heliyon)
This study established a nine-DE_GRG-based prognostic signature, which independently predicted ccRCC prognosis. This finding emphasizes that GRGs are stratification factors for the precise prognosis of ccRCC.
Journal
|
FUT3 (Fucosyltransferase 3) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2) • ST8SIA4 (ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-Sialyltransferase 4)
over1year
Immune-related glycosylation genes based classification predicts prognosis and therapy options of osteosarcoma. (PubMed, Gene)
Results from TIDE algorithm and immunotherapy datasets suggested the C2 type's preference of immune checkpoint inhibitors (ICIs), while data of GDSC, CMap analysis and cell experiments indicated that C1 type was sensitivity to MEK inhibitor PD0325901...In summary, the classification and risk score based on IRGGs effectively predicted the prognosis and therapy options of osteosarcoma. Further studies on IRGGs may contribute to the understanding of cancer immunity in osteosarcoma.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • FUT7 (Fucosyltransferase 7) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)
|
TMB-H
|
Gomekli (mirdametinib)
over1year
Multiple Administration of Dexamethasone Possesses a Deferred Long-Term Effect to Glycosylated Components of Mouse Brain. (PubMed, Neurol Int)
A correlation analysis revealed an association between the mRNA level of the GR and the mRNA level of 8 of the 14 proteoglycans-coding and 4 of the 13 heparan sulfate metabolism-involved genes supporting GR involvement in the DXM regulation of the expression of these genes. In summary, multiple DXM administrations led to an increase in the total GAG content and reorganized the brain extracellular matrix in terms of its glycosylation pattern.
Preclinical • Journal
|
ACAN (Aggrecan) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)
|
dexamethasone
almost2years
Pan-cancer analysis of HS6ST2: associations with prognosis, tumor immunity, and drug resistance. (PubMed, Am J Transl Res)
Overall, this study provides a comprehensive understanding of HS6ST2 in CESC, KICH, LUAD, and STAD, emphasizing its potential as a prognostic biomarker and therapeutic target.
Journal • Pan tumor
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)
2years
Downregulation of HS6ST2 Inhibits Cervical Cancer Cell Migration and Invasion in Vivo and in Vitro. (PubMed, Discov Med)
The clinicopathological features and the survival time of the patients significantly correlate with the level of HS6ST2 expression in CC tissue samples.
Preclinical • Journal
|
HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)
over2years
A Novel HPV/Host DNA Methylation-Score and Detection of Cervical Adenocarcinoma. (PubMed, J Natl Cancer Inst)
HPV16/18/45-infected women with Methylation-Scores in the highest quartile had very high odds of AIS/ADC, suggesting they may warrant careful histologic evaluation of the cervical transition zone (eg, conization or LEEP).
Journal • Epigenetic controller
|
HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)
almost3years
Identification of Five Tumor Antigens for Development and Two Immune Subtypes for Personalized Medicine of mRNA Vaccines in Papillary Renal Cell Carcinoma. (PubMed, J Pers Med)
Compared with IS2, IS1 exhibited a significantly immune-suppressive phenotype, which largely weakened the efficacy of the mRNA vaccine. Overall, our study provides some insights for the design of anti-PRCC mRNA vaccines and, more importantly, the selection of suitable patients to be vaccinated.
Journal
|
SMYD3 (SET And MYND Domain Containing 3) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)
3years
Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments. (PubMed, Front Oncol)
Meanwhile, the estimated IC50 of seven drugs differs significantly between two risk groups, including Cisplatin, Docetaxel, Doxorubicin, Gefitinib, Paclitaxel, Sunitinib and Vinorelbine. In summary, our study identified the molecules significantly affecting M2 macrophage infiltration and identified a prognosis signature that robustly indicated patients prognosis. Moreover, we validated the cancer-promoting effect of HNMT using in vitro experiments.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CAPZA2 (Capping Actin Protein Of Muscle Z-Line Subunit Alpha 2) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2) • TM6SF1 (Transmembrane 6 Superfamily Member 1)
|
cisplatin • gefitinib • paclitaxel • docetaxel • sunitinib • doxorubicin hydrochloride • vinorelbine tartrate
over4years
Identification of the miRNA signature and key genes in colorectal cancer lymph node metastasis. (PubMed, Cancer Cell Int)
In summary, miRNAs and genes with potential as biomarkers were found and a novel miRNA-mRNA network was established for CRC lymph node metastasis by systematic bioinformatic analysis and experimental validation. This network may be used as a potential biomarker in the development of lymph node metastatic CRC.
Journal
|
MIR100 (MicroRNA 100) • MIR99A (MicroRNA 99a) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)
over4years
Crosstalk Between DNA Methylation and Gene Mutations in Colorectal Cancer. (PubMed, Front Oncol)
When comparing the methylation profile according to mutation status, we found that six genes (SFRP2, DKK2, PCDH10, TMEFF2, SFRP1, HS3ST2) showed a methylation level higher in BRAF positive cases than BRAF negative cases. The molecular sub-classification of CRC according to mutations and epigenetic modifications may help to identify epigenetic biomarkers useful in designing personalized strategies to improve patient outcomes.
Journal • Epigenetic controller
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RUNX3 (RUNX Family Transcription Factor 3) • DKK3 (Dickkopf WNT Signaling Pathway Inhibitor 3) • SFRP1 (Secreted frizzled related protein 1) • WIF1 (WNT Inhibitory Factor 1) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)
|
KRAS mutation • BRAF mutation
over4years
HS3ST2 and Its Related Molecules as Potential Biomarkers for Predicting Lymph Node Metastasis in Patients with Colorectal Cancer. (PubMed, Onco Targets Ther)
By using microarray and bioinformatics analyses, differentially expressed miRNAs were identified and a complete gene network was constructed. To our knowledge, HS3ST2 and related molecules including hsa-miR-100 and hsa-miR-99a were firstly identified as potential biomarkers in the development of lymph node metastatic colorectal cancer.
Clinical • Journal
|
MIR100 (MicroRNA 100) • MIR99A (MicroRNA 99a) • HS3ST2 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 2)